New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 9, 2014
08:35 EDTKERXKeryx Zerenex phase 2 data presentation selected for Kidney Foundation meeting
Keryx Biopharmaceuticals announced that Phase 2 clinical results of Zerenex in non-dialysis dependent chronic kidney disease patients with elevated serum phosphorus and iron deficiency anemia has been selected as a Late Breaking oral presentation at the National Kidney Foundation 2014 Spring Clinical Meeting, taking place April 22-26. This presentation, entitled "Zerenex for the Treatment of Iron-Deficiency Anemia and Reduction of Serum Phosphate in Non-Dialysis Dependent CKD," will be made during the Late Breaking Session on Friday, April 25.
News For KERX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 26, 2015
08:48 EDTKERXKeryx management to meet with JMP SEcurities
Subscribe for More Information
March 23, 2015
13:43 EDTKERXKeryx mentioned cautiously in a Seeking Alpha Pro article
Subscribe for More Information
March 20, 2015
07:55 EDTKERXKeryx survey results positive, says Oppenheimer
After surveying 50 nephrologists/nurses/dietitians at U.S. dialysis clinics, Oppenheimer reported that dialysis providers it surveyed expect to prescribe Keryx's Auryxia in 11% of new starts and about 12% of switchers . As a result of this data points and other data from the survey, the firm expects Auryxia prescription trends to improve. It keeps an $18 price target and Outperform rating on the shares.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use